{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:29Z","timestamp":1792511549444,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca Holding France SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.10.013","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:58:41Z","timestamp":1729789121000},"page":"e173-e181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-7261","authenticated-orcid":false,"given":"Lo\u00efc","family":"Ysebaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Malartre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Portalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-6463","authenticated-orcid":false,"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-0047","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Zerbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2024.10.013_bib0001","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s10238-023-01007-2","article-title":"Expert consensus on the management of chronic lymphocytic leukaemia in Asia","volume":"23","author":"Tse","year":"2023","journal-title":"Clin Exp Med"},{"issue":"1","key":"10.1016\/j.clml.2024.10.013_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clml.2024.10.013_bib0003","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL Study Group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.10.013_bib0004","article-title":"Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice","volume":"11","author":"O'Brien","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.10.013_bib0005","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1080\/10428194.2022.2098289","article-title":"Practical management of chronic lymphocytic leukemia with acalabrutinib","volume":"63","author":"Kuss","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2024.10.013_bib0006","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.013_bib0007","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1111\/bcp.15278","article-title":"Acalabrutinib CYP3A-mediated drug-drug interactions: clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy","volume":"88","author":"Chen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.013_bib0008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"10.1016\/j.clml.2024.10.013_bib0009","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"10232","key":"10.1016\/j.clml.2024.10.013_bib0010","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clml.2024.10.013_bib0011","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.10.013_bib0012","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL","volume":"6","author":"Awan","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2024.10.013_bib0013","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.10.013_bib0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.013_bib0015","first-page":"185","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.clml.2024.10.013_bib0016","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/03007995.2020.1816946","article-title":"Delphi, non-RAND modified Delphi, RAND\/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review","volume":"36","author":"Jandhyala","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.clml.2024.10.013_bib0017","doi-asserted-by":"crossref","first-page":"e6953","DOI":"10.1002\/cam4.6953","article-title":"Real-world analysis of adverse event rates after initiation of ibrutinib among medicare beneficiaries with chronic lymphocytic leukemia","volume":"13","author":"Huntington","year":"2024","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.clml.2024.10.013_bib0018","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00277-020-04045-y","article-title":"Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study","volume":"99","author":"Zerbit","year":"2020","journal-title":"Ann Hematol"},{"issue":"31","key":"10.1016\/j.clml.2024.10.013_bib0019","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase iii trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.10.013_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.10.013_bib0021","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.clml.2024.10.013_bib0022","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3324\/haematol.2018.207183","article-title":"Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions","volume":"104","author":"Series","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.10.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000969472.42363.47","article-title":"P642: a matching-adjusted indirect comparison of the efficacy and safety of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"7","author":"Skarbnik","year":"2023","journal-title":"HemaSphere"},{"issue":"11","key":"10.1016\/j.clml.2024.10.013_bib0024","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","article-title":"An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL","volume":"8","author":"Kittai","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2024.10.013_bib0025","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/bloodadvances.2023011569","article-title":"Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study","volume":"8","author":"Samples","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.10.013_bib0026","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.013_bib0027","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/blood-2023-174727","article-title":"Cumulative review of hypertension in patients with Chronic Lymphocytic Leukemia (CLL) and other hematologic malignancies treated with acalabrutinib","volume":"142","author":"Ferrajoli","year":"2023","journal-title":"Blood"},{"issue":"41","key":"10.1016\/j.clml.2024.10.013_bib0028","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.clml.2024.10.013_bib0029","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajh\/hpy185","article-title":"Schedules for self-monitoring blood pressure: a systematic review","volume":"32","author":"Hodgkinson","year":"2019","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.clml.2024.10.013_bib0030","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.10.013_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.995522","article-title":"Data mining and safety analysis of BTK inhibitors: a pharmacovigilance investigation based on the FAERS database","volume":"13","author":"Wan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.013_bib0032","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.3747\/co.27.6795","article-title":"Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia","volume":"27","author":"Banerji","year":"2020","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.013_bib0033","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.clml.2024.10.013_bib0034","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.10.013_bib0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/psp4.12408","article-title":"Evaluation of the drug-drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach","volume":"8","author":"Zhou","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clml.2024.10.013_bib0036","unstructured":"European Public Assessment Report. Calquence : EPAR - Product information. 2024; https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/calquence-epar-product-information_en.pdf. Accessed July 8, 2024."},{"issue":"12","key":"10.1016\/j.clml.2024.10.013_bib0037","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.10.013_bib0038","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2648.2003.02537.x","article-title":"The Delphi technique: myths and realities","volume":"41","author":"Powell","year":"2003","journal-title":"J Adv Nurs"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502402398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502402398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:26Z","timestamp":1739364446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502402398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S215226502402398X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}